The prolonged war in Ukraine is having a strong impact on all sectors of the Ukrainian society, including biomedical research. Although the material and psychological conditions are challenging, the country and its researchers are courageously managing to continue their activities. This perspective paper describes the multiple challenges faced by Ukrainian biomedical researchers during wartime and outlines strategies to support and enhance collaboration with the global scientific community.
View Article and Find Full Text PDFThis study investigated the prognostic value of the chemokine C-C motif ligand 2 (CCL2) and its receptor C-C motif chemokine receptor 2 (CCR2) expression in locally advanced prostate cancer treated with radiotherapy and androgen deprivation using the 10-year outcome data from the TROG 03.04 RADAR clinical trial. CCL2 and CCR2 protein expression in prostate cancer biopsies at the time of diagnosis were quantified by immunohistochemistry and digital quantification.
View Article and Find Full Text PDFThe field of cancer neuroscience has begun to define the contributions of nerves to cancer initiation and progression; here, we highlight the future directions of basic and translational cancer neuroscience for malignancies arising outside of the central nervous system.
View Article and Find Full Text PDFMost of annelids grow all over their asexual life through the continuous addition of segments from a special zone called "segment addition zone" (SAZ) adjacent to the posterior extremity called pygidium. Amputation of posterior segments leads to regeneration (posterior regeneration-PR) of the pygidium and a new SAZ, as well as new segments issued from this new SAZ. Amputation of anterior segments leads some species to regeneration (anterior regeneration-AR) of the prostomium and a SAZ which produces new segments postero-anteriorly as during PR.
View Article and Find Full Text PDFTriple negative breast cancer (TNBC) is an aggressive malignancy for which chemotherapy remains the standard treatment. However, between 3 and 5 years after chemotherapy, about half patients will relapse and it is essential to identify vulnerabilities of cancer cells surviving neoadujuvant therapy. In this study, we established persistent TNBC cell models after treating MDA-MB-231 and SUM159-PT TNBC cell lines with epirubicin and cyclophosphamide, and then with paclitaxel, for a total of 18 weeks.
View Article and Find Full Text PDF